Sign in

    Elias Lenard • JPMorgan Chase & Co.

    Elias Lenard's questions to Immunocore Holdings PLC (IMCR) leadership

    Elias Lenard's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Elias Lenard, on behalf of Jessica Fye at JPMorgan, inquired about the upcoming brenetafusp ovarian cancer data at ESMO, asking about patient numbers, the mono/combo split, success benchmarks, and progress in the platinum-sensitive setting.

    Answer

    David Berman, Head of R&D, said the ESMO dataset size will be similar to the ASCO melanoma data, primarily monotherapy but with more combinations. He noted existing chemotherapy benchmarks are low, with response rates under 10%. Mohammed Dar, an executive, added that the study now allows moving into earlier, platinum-sensitive lines to test combinations with therapies like bevacizumab and platinum doublets.

    Ask Fintool Equity Research AI

    Elias Lenard's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Elias Lenard, on behalf of Jessica Fye at JPMorgan, inquired about the upcoming brenetafusp ovarian cancer data at ESMO, including patient numbers and success benchmarks, and asked about progress in the platinum-sensitive setting.

    Answer

    David Berman, Head of R&D, said the ESMO data set will be similar in size to the ASCO melanoma data, mostly monotherapy, with success benchmarked against poor chemotherapy outcomes (single-digit response rates). Mohammed Dar, an executive, added that the study is now moving into earlier, platinum-sensitive lines to test combinations with bevacizumab and platinum doublets.

    Ask Fintool Equity Research AI